Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-induced Nausea and Vomiting in Children

Archives of Medical Research

Volumn 39, Issue 6, 2008, Pages 601-606

  Sepúlveda Vildósola, Ana Carolina ^a   Betanzos Cabrera, Yadira ^a   Lastiri, Graciela Gascón ^a   Rivera Márquez, Hugo ^a   Villasis Keever, Miguel Angel ^a   del Angel, Volkmar Wanzke ^a   Díaz, Fernando Cerecedo ^a   López Aguilar, Enrique ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Antiemetic treatment; Palonosetron; Pediatric cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; ONDANSETRON; PALONOSETRON;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; MALE; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL; RISK; SCHOOL CHILD; STATISTICAL ANALYSIS; STUDENT T TEST;

ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HUMANS; ISOQUINOLINES; MALE; NAUSEA; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 47749145323     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.04.007     Document Type: Article

References (31)

1. Fajardo G.A., Mejía A.J.M., Gómez Delgado M., Mendoza Sánchez A., Garduño Espinosa H., and Martínez García J. Epidemiología de las neoplasias malignas en niños residentes del Distrito Federal (1982-1991). Bol Med Hosp Infant Mex 52 (1995) 513-522
2. Hesketh P.J. Defining the emetogenicity of cancer chemotherapy regimens. Oncologist 4 (1999) 191-196
3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology antiemesis v1. 2005. March 1, 2005.
4. Multinational Association of Supportive care in Cancer. 2004 Perugia Antiemetic Consensus Guidelines. Support Care Cancer 13 (2005) 85-86
5. Gregory R.E., and Ettinger D.S. 5-HT3 receptor antagonist for the prevention of chemotherapy-induced vomiting. Drugs 55 (1998) 173-189
6. De Vita V.T., Hellman S., and Rosenberg S.A. Nausea and vomiting. Cancer, Principles and Practice of Oncology (2005), Lippincott Williams and Wilkins, Philadelphia pp. 2515-2522
7. American Society of Health Systems. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting. Am J Health System Pharm 56 (1999) 729-764
8. Walton S.M. Advance in use of 5-HT3 receptors antagonist. Exp Opin Pharmacother 1 (2000) 207-223
9. Egerer G., and Hegenbart U. Treatment of chemotherapy induced emesis. Antibiot Chemother 1 (2000) 207-223
10. Hesketh P.J. Comparative review of 5-HT3 receptor antagonist in the treatment of acute induced vomiting. Cancer Invest 18 (2000) 163-173
11. Jantunen I.T., and Kataja V.W. An overview of randomized studies comparing 5-HT3 and conventional antiemetics. Eur J Cancer 33 (1997) 66-74
12. Johnston D. Preventing nausea and vomiting during days 2-7. Proc Am Soc Clin Oncol 14 (1995) 529
13. Grunberg S.M., and Deuson R.R. Incidence of chemotherapy-induced nausea and emesis. Cancer 100 (2004) 2261-2268
14. Hickok J.T., and Roscoe J.A. Nausea and emesis remain significant problems of chemotherapy. Cancer 97 (2003) 2880-2886
15. Kaizer L., Warr D., Hoskins P., Latreille J., Lofters W., Yau J., Palmer M., et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexametazone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12 (1994) 1050-1057
16. Osoba D., Zee B., and Warr D. Effect of postchemotherapeutic nausea and vomiting. Support Care Cancer 5 (1997) 307-313
17. Ihbe-Heffinger A., and Ehinken B. The impact of delayed chemotherapy induced nausea and vomiting on patients. Ann Oncol 15 (2004) 526-536
18. Wong E.H.F., Clark R., Leung E., Loury D., Bonhaus D.W., Jakeman L., et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors in vitro. Br J Phramcol 114 (1995) 851-859
19. Stotz R., and Cyong J.C. Pharmacokinetic and safety evaluation of palonosetron in US subjects. J Clin Pharmacol 44 (2004) 520-531
20. Massaro A.M., and Lenz S. A novel antiemetic for chemotherapy-induced vomiting. Ann Pharmacother 39 (2005) 77-85
21. American Society of Clinical Oncology, Kris M.G., Hesketh P.J., Somerfield M.R., Feyer P., Clark-Snow R., Koeller J.M., et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 24 (2006) 2932-2947
22. Shah A., DeGroot T., and Apseloff G. Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. J Clin Pharmacol 46 (2006) 1139-1145
23. Eisenberg P., and Figueroa V. Improved prevention of moderate CINV with palonosetron. Cancer 98 (2003) 2473-2482
24. Eisenberg P., and Mackintosh F.R. Efficacy, safety of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy. Ann Oncol 15 (2004) 330-337
25. Aapro M.S., Grunberg S.M., Manikhas G.M., Olivares G., Suarez T., Tjulandin S.A., et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17 (2006) 1441-1449
26. Eisenberg P., Figueroa-Vadillo J., Zamora R., Charu V., Hajdenberg J., Cartmell A., et al. 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98 (2003) 2473-2482
27. Gralla R., and Lichinster M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 14 (2003) 1570-1577
28. Kadota R., Shen V., and Messinger Y. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a stratified, double-blind, phase 3, randomized study. Proc Am Soc Clin Oncol (2007) General Poster Session
29. Murry D.J., Riva L., and Poplack D.G. Impact of nutrition on pharmacokinetics of antineoplastic agents. Int J Cancer 11 Suppl (1998) 48-51
30. Kris M.G., and Hesketh D.S. Consensus purpose for the prevention of acute and delayed vomiting and nausea. Support Care 13 (2005) 85-96
31. Del Favero A., and Rolla F. Reducing chemotherapy-induced vomiting. Drug Saf 9 (1993) 410-428